Takara
PCR How to Select the Best PCR Enzyme Guide to Takara PCR Polymerases High Fidelity PCR High Speed PCR High Performance PCR DNA Bisulphite Modification Real Time (qPCR) Kits General PCR Products RT-PCR and RACE Food Pathogen Detection & Screening Kits PCR Probes & Primer Sets Molecular Biology Cloning, Mapping & cDNA Synthesis Gene Transfer & Expression RNA/Protein/DNA Extraction Nucleic Acids Electrophoresis Instrumentation DNA Labeling & Detection Kits Sequencing, Mutagenesis & Mutation Analysis Molecular Biology Reagents Restriction Enzymes Modifying Enzymes: Kinases & RT Modifying Enzymes: Phosphatases Modifying Enzymes: Ligases Modifying Enzymes: DNA Polymerase Modifying Enzymes: RNA Polymerase Modifying Enzymes: Nucleases Modifying Enzymes: Rnase Inhibitor DNA Microarray Accessories Cell Biology Apoptosis Antibodies Bone Research Products Cell Adhesion & Extracellular Matrix Cell Differentiation Kit Cell Proliferation & Viability Signal Transduction Viral & Microbial Detection Protein Research Recombinant Protein Folding & Expression C-Terminal Isolation & Analysis N-Terminal Deblocking & Analysis Protein Fragmentation Protease Inhibition Glycobiology Glycobiology Kits Related Enzymes Order Products
About Takara Bio USA Clontech-Takara Bio USA Merger Contact Us Takara Subsidiares and Distributors How to Order Career Opportunities
Press Releases Trade Shows Company News
Home > News&Events > Press Releases

Press Release

Title Date
Takara Bio Announces Their Mid-Term Management Plan
 05/13/2008
Clinical Research Begins at Tianjin Cancer Institute and Hospital Utilizing RetroNectin®
Cancer immunotherapy clinical research using the RetroNectin®: T-cell expansion culture system has begun at Tianjin Cancer Institute & Hospital, China.
 04/30/2008
Takara Bio Constructs 3rd Factory Building
To increase the production capacity of research reagents at Takara Bio's subsidiary, Takara Biotechnology (Dalian) Co., Ltd, a 3rd factory building has been constructed.
01/30/2008
MolMed S.p.A. to Start Phase III Trial
MolMed S.p.A., a strategic partner of Takara Bio in gene therapy, obtains a regulatory approval to start a Phase III trial of HSV-TK gene therapy for high risk acute leukemia in Italy.
 01/22/2008
Pre-clinical Study to Use RetroNectin®
Takara Bio to enter into an M-CRADA with Dr. Rosenberg's group at NCI initiating pre-clinical studies of gene therapy using RetroNectin®-expansion culture system.
 01/09/2008
Takara Bio Grants Kemp Biotechnologies a license for LA-PCR Technology
 07/19/2007
Takara Bio Grants Transgenomic a License for LA-PCR Technology
 05/07/2007
Takara Bio grants a non-exclusive License of its Proprietary Antibiotic Aureobasidin A-related Patents to AureoGen Biosciences for Development of Novel Drugs
01/29/2007